RCUS: Arcus Biosciences, Inc. Stock

by  •  • Comments Off on RCUS: Arcus Biosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,337.90
Enterprise Value ($M) 1,204.90
Book Value ($M) 565.00
Book Value / Share 6.17
Price / Book 2.37
NCAV ($M) 440.00
NCAV / Share 4.81
Price / NCAV 3.04

Profitability (mra)
Return on Invested Capital (ROIC) -0.42
Return on Assets (ROA) -0.23
Return on Equity (ROE) -0.52

Liquidity (mrq)
Quick Ratio 5.24
Current Ratio 5.24

Balance Sheet (mrq) ($M)
Current Assets 1,127.00
Assets 1,252.00
Liabilities 687.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Fmr Llc 4.89 -5.52
11-08 13G/A BlackRock, Inc. 10.60 0.00
10-17 13G/A State Street Corp 3.30 -28.97
02-13 13G/A Vanguard Group Inc 6.25 7.03
01-31 13D/A Gilead Sciences Inc 35.00 23.24

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURS
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PUR
2024-02-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-21 211,725 587,106 36.06
2024-11-20 176,371 478,525 36.86
2024-11-19 50,186 280,584 17.89
2024-11-18 118,091 557,447 21.18

(click for more detail)

Similar Companies
PFE – Pfizer Inc. PRGO – Perrigo Company plc
QGEN – Qiagen N.V. RFL – Rafael Holdings, Inc.
USNA – USANA Health Sciences, Inc.


Financial data and stock pages provided by
Fintel.io